Clal Biotechnology Industries Stock Fundamentals
| CBI Stock | 37.80 1.40 3.85% |
Clal Biotechnology Industries fundamentals help investors to digest information that contributes to Clal Biotechnology's financial success or failures. It also enables traders to predict the movement of Clal Stock. The fundamental analysis module provides a way to measure Clal Biotechnology's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Clal Biotechnology stock.
Clal |
Clal Biotechnology Industries Company Operating Margin Analysis
Clal Biotechnology's Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Current Clal Biotechnology Operating Margin | (0.86) % |
Most of Clal Biotechnology's fundamental indicators, such as Operating Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Clal Biotechnology Industries is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
| Competition |
Based on the recorded statements, Clal Biotechnology Industries has an Operating Margin of -0.8593%. This is 97.55% lower than that of the Biotechnology sector and 99.23% lower than that of the Health Care industry. The operating margin for all Israel stocks is 84.4% lower than that of the firm.
Clal Biotechnology Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Clal Biotechnology's current stock value. Our valuation model uses many indicators to compare Clal Biotechnology value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Clal Biotechnology competition to find correlations between indicators driving Clal Biotechnology's intrinsic value. More Info.Clal Biotechnology Industries is rated fifth in return on equity category among its peers. It is rated fourth in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Clal Biotechnology by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Clal Biotechnology's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Clal Operating Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Clal Biotechnology's direct or indirect competition against its Operating Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Clal Biotechnology could also be used in its relative valuation, which is a method of valuing Clal Biotechnology by comparing valuation metrics of similar companies.Clal Biotechnology is currently under evaluation in operating margin category among its peers.
Clal Fundamentals
| Return On Equity | -0.45 | |||
| Return On Asset | -0.12 | |||
| Profit Margin | (1.14) % | |||
| Operating Margin | (0.86) % | |||
| Current Valuation | 89.12 M | |||
| Shares Outstanding | 156.85 M | |||
| Shares Owned By Insiders | 64.58 % | |||
| Price To Earning | (218.28) X | |||
| Price To Book | 0.68 X | |||
| Price To Sales | 2.79 X | |||
| Revenue | 76.96 M | |||
| Gross Profit | 10.72 M | |||
| EBITDA | (98.18 M) | |||
| Net Income | (89.58 M) | |||
| Cash And Equivalents | 94.71 M | |||
| Cash Per Share | 0.59 X | |||
| Total Debt | 52.28 M | |||
| Debt To Equity | 6.30 % | |||
| Current Ratio | 3.67 X | |||
| Book Value Per Share | 0.84 X | |||
| Cash Flow From Operations | (41.33 M) | |||
| Earnings Per Share | (0.57) X | |||
| Target Price | 30.0 | |||
| Number Of Employees | 21 | |||
| Beta | 0.9 | |||
| Market Capitalization | 122.65 M | |||
| Total Asset | 444.92 M | |||
| Retained Earnings | (823 M) | |||
| Working Capital | 193 M | |||
| Current Asset | 254 M | |||
| Current Liabilities | 61 M | |||
| Z Score | -0.2 | |||
| Annual Yield | 0.18 % | |||
| Net Asset | 444.92 M |
About Clal Biotechnology Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Clal Biotechnology Industries's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Clal Biotechnology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Clal Biotechnology Industries based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Clal Biotechnology Industries Ltd. is a private equity and venture capital firm specializing in development stage, pre-clinical incubation, seed, start-up, early venture, emerging growth, mid venture, late venture, PIPEs, and growth capital stages of financing. It operates as a subsidiary of Clal Industries and Investments Ltd. CLAL BIOTECHNOLOGY operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Clal Stock
Clal Biotechnology financial ratios help investors to determine whether Clal Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Clal with respect to the benefits of owning Clal Biotechnology security.